Literature DB >> 19218827

Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire.

Maurizio Fava1, Dan V Iosifescu, Paola Pedrelli, Lee Baer.   

Abstract

BACKGROUND: We have recently developed the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ), a brief scale to measure cognitive and executive dysfunction in mood and anxiety disorders, and we here report on its reliability and validity.
METHODS: The internal consistency of the CPFQ was assessed by computing Cronbach's coefficient alpha based upon the average intercorrelation of the 7 items of the CPFQ in a sample of depressed outpatients and by factor analyzing data from the same sample to confirm that the scale is unifactorial and measuring a single construct. Test-retest reliability of the CPFQ was assessed in a different sample of depressed outpatients by computing Pearson's correlation coefficient between pretreatment screening scores and pretreatment baseline scores. Sensitivity to change of the CPFQ was assessed by computing the dependent t test for the subjects in the active treatment condition in the second sample of depressed outpatients. Finally, convergent validity for the CPFQ was assessed in two different ways.
RESULTS: We found that the CPFQ is a unifactorial scale, with strong internal consistency. It has good temporal stability as indicated by high test-retest reliability. The CPFQ was also found to be sensitive to change with treatment and displayed convergent validity by significant correlations with other measures of sleepiness, fatigue, apathy and neuropsychological functioning. Although, as expected, the CPFQ was significantly correlated with a measure of depression, the moderate correlation (r approximately 0.30) indicates that the CPFQ is measuring a different construct.
CONCLUSION: In summary, the CPFQ is a unifactorial scale, with strong internal consistency, good temporal stability and sensitivity to change with treatment. Further studies will be needed to assess the validity and reliability of this instrument in other psychiatric and neuropsychiatric conditions associated with cognitive dysfunction. 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19218827     DOI: 10.1159/000201934

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  33 in total

1.  Fatigue as a residual symptom of depression.

Authors:  Steven D Targum; Maurizio Fava
Journal:  Innov Clin Neurosci       Date:  2011-10

2.  A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder.

Authors:  Dawn F Ionescu; Maurizio Fava; Daniel Ju Hyung Kim; Lee Baer; Richard C Shelton; Cristina Cusin
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

3.  Correlates of irritability in college students with depressive symptoms.

Authors:  Paola Pedrelli; Maren Nyer; Daphne Holt; Brianna R Bakow; Maurizio Fava; Lee Baer; Clair Cassiello; Maura Mulligan; Cristina Cusin; Amy Farabaugh
Journal:  J Nerv Ment Dis       Date:  2013-11       Impact factor: 2.254

4.  Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.

Authors:  Hitoshi Sakurai; Christina Dording; Albert Yeung; Simmie Foster; Felipe Jain; Trina Chang; Nhi-Ha Trinh; Richard Bernard; Sean Boyden; Syed Z Iqbal; Samuel T Wilkinson; Sanjay J Mathew; David Mischoulon; Maurizio Fava; Cristina Cusin
Journal:  J Affect Disord       Date:  2019-07-02       Impact factor: 4.839

5.  Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders.

Authors:  Diane Warden; Katherine Sanchez; Tracy Greer; Thomas Carmody; Robrina Walker; Adriane Dela Cruz; Marisa Toups; Chad Rethorst; Madhukar H Trivedi
Journal:  Psychiatry Res       Date:  2016-09-15       Impact factor: 3.222

6.  Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial.

Authors:  Manish K Jha; Abu Minhajuddin; Tracy L Greer; Thomas Carmody; A John Rush; Madhukar H Trivedi
Journal:  Am J Psychiatry       Date:  2016-08-13       Impact factor: 18.112

7.  Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder.

Authors:  Kamilla W Miskowiak; Maj Vinberg; Catherine J Harmer; Hannelore Ehrenreich; Gitte M Knudsen; Julian Macoveanu; Allan R Hansen; Olaf B Paulson; Hartwig R Siebner; Lars V Kessing
Journal:  Trials       Date:  2010-10-13       Impact factor: 2.279

8.  Factors that distinguish college students with depressive symptoms with and without suicidal thoughts.

Authors:  Maren Nyer; Daphne J Holt; Paola Pedrelli; Maurizio Fava; Victoria Ameral; Clair F Cassiello; Matthew K Nock; Margaret Ross; Dori Hutchinson; Amy Farabaugh
Journal:  Ann Clin Psychiatry       Date:  2013-02       Impact factor: 1.567

9.  Development of a clinician-administered National Institutes of Health-Brief Fatigue Inventory: A measure of fatigue in the context of depressive disorders.

Authors:  Leorey N Saligan; David A Luckenbaugh; Elizabeth E Slonena; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2015-06-24       Impact factor: 4.791

10.  Relationship between sleep disturbance and depression, anxiety, and functioning in college students.

Authors:  Maren Nyer; Amy Farabaugh; Kiki Fehling; David Soskin; Daphne Holt; George I Papakostas; Paola Pedrelli; Maurizio Fava; Angela Pisoni; Ottavio Vitolo; David Mischoulon
Journal:  Depress Anxiety       Date:  2013-05-16       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.